They reported that TMPRSS2:ERG fusions occur in about 50 % of cancers and that they are unrelated to PSA recurrence in patients treated by radical prostatectomy [5] while it is possible, that fusion positive cancers might react better to anti-androgen therapy than fusion negative tumors [6, 7]. The gene discussed is ERG; the disease is cancer.